O	0	7	Patient
O	7	8	-
O	8	16	reported
O	17	25	symptoms
O	26	29	and
O	30	37	quality
O	38	40	of
O	41	45	life
O	46	52	during
O	53	62	treatment
O	63	67	with
B-intervention	68	77	tamoxifen
O	78	80	or
B-control	81	91	raloxifene
O	92	95	for
O	96	102	breast
O	103	109	cancer
O	110	120	prevention
O	120	121	:
O	122	125	the
O	126	131	NSABP
O	132	137	Study
O	138	140	of
O	141	150	Tamoxifen
O	151	154	and
O	155	165	Raloxifene
O	166	167	(
O	167	171	STAR
O	171	172	)
O	173	174	P
O	174	175	-
O	175	176	2
O	177	182	trial
O	182	183	.

O	184	193	Tamoxifen
O	194	197	has
O	198	202	been
O	203	211	approved
O	212	215	for
O	216	222	breast
O	223	229	cancer
O	230	234	risk
O	235	244	reduction
O	245	247	in
O	248	252	high
O	252	253	-
O	253	257	risk
O	258	263	women
O	263	264	,
O	265	268	but
O	269	272	how
O	273	283	raloxifene
O	284	292	compares
O	293	297	with
O	298	307	tamoxifen
O	308	310	is
O	311	318	unknown
O	318	319	.

O	320	322	To
O	323	330	compare
O	331	334	the
O	335	346	differences
O	347	349	in
O	350	357	patient
O	357	358	-
O	358	366	reported
O	367	375	outcomes
O	375	376	,
O	377	384	quality
O	385	387	of
O	388	392	life
O	393	394	[
O	394	397	QOL
O	397	398	]
O	398	399	,
O	400	403	and
O	404	412	symptoms
O	413	415	in
O	416	421	Study
O	422	424	of
O	425	434	Tamoxifen
O	435	438	and
O	439	449	Raloxifene
O	450	451	(
O	451	455	STAR
O	455	456	)
O	457	469	participants
O	470	472	by
O	473	482	treatment
O	483	493	assignment
O	493	494	.

O	495	499	STAR
O	500	503	was
O	504	505	a
O	506	512	double
O	512	513	-
O	513	518	blind
O	518	519	,
O	520	530	randomized
O	531	536	phase
O	537	538	3
O	539	549	prevention
O	550	555	trial
O	556	564	designed
O	565	567	to
O	568	576	evaluate
O	577	580	the
O	581	589	relative
O	590	598	efficacy
O	599	601	of
O	602	612	raloxifene
O	613	615	vs
O	616	625	tamoxifen
O	626	628	in
O	629	637	reducing
O	638	641	the
O	642	651	incidence
O	652	654	of
O	655	663	invasive
O	664	670	breast
O	671	677	cancer
O	678	680	in
B-eligibility	681	685	high
I-eligibility	685	686	-
I-eligibility	686	690	risk
I-eligibility	691	705	postmenopausal
I-eligibility	706	711	women
O	711	712	.

O	713	720	Between
O	721	725	July
O	726	727	1
O	727	728	,
O	729	733	1999
O	733	734	,
O	735	738	and
O	739	747	November
O	748	749	4
O	749	750	,
O	751	755	2004
O	755	756	,
B-total-participants	757	759	19
I-total-participants	759	760	,
I-total-participants	760	763	747
O	764	776	participants
O	777	781	were
O	782	790	enrolled
O	791	793	at
O	794	801	centers
O	802	812	throughout
B-location	813	818	North
I-location	819	826	America
O	826	827	,
O	828	832	with
O	833	834	a
O	835	841	median
O	842	851	potential
O	852	858	follow
O	858	859	-
O	859	861	up
O	862	866	time
O	867	869	of
O	870	871	4
O	871	872	.
O	872	873	6
O	874	879	years
O	880	881	(
O	881	886	range
O	886	887	,
O	888	889	1
O	889	890	.
O	890	891	2
O	891	892	-
O	892	893	6
O	893	894	.
O	894	895	5
O	896	901	years
O	901	902	)
O	902	903	.

O	904	911	Patient
O	911	912	-
O	912	920	reported
O	921	929	symptoms
O	930	934	were
O	935	944	collected
O	945	949	from
O	950	953	all
O	954	966	participants
O	967	972	using
O	973	974	a
O	975	977	36
O	977	978	-
O	978	982	item
O	983	990	symptom
O	991	1000	checklist
O	1000	1001	.

O	1002	1009	Quality
O	1010	1012	of
O	1013	1017	life
O	1018	1021	was
O	1022	1030	measured
O	1031	1035	with
O	1036	1039	the
O	1040	1047	Medical
O	1048	1056	Outcomes
O	1057	1062	Study
O	1063	1068	Short
O	1068	1069	-
O	1069	1073	Form
O	1074	1080	Health
O	1081	1087	Survey
O	1088	1089	(
O	1089	1091	SF
O	1091	1092	-
O	1092	1094	36
O	1094	1095	)
O	1095	1096	,
O	1097	1100	the
O	1101	1107	Center
O	1108	1111	for
O	1112	1125	Epidemiologic
O	1126	1133	Studies
O	1133	1134	-
O	1134	1144	Depression
O	1145	1146	(
O	1146	1149	CES
O	1149	1150	-
O	1150	1151	D
O	1151	1152	)
O	1152	1153	,
O	1154	1157	and
O	1158	1161	the
O	1162	1169	Medical
O	1170	1178	Outcomes
O	1179	1184	Study
O	1185	1191	Sexual
O	1192	1200	Activity
O	1201	1214	Questionnaire
O	1215	1217	in
O	1218	1219	a
O	1220	1228	substudy
O	1229	1231	of
B-total-participants	1232	1236	1983
O	1237	1249	participants
O	1249	1250	,
O	1251	1257	median
O	1258	1267	potential
O	1268	1274	follow
O	1274	1275	-
O	1275	1277	up
O	1278	1279	5
O	1279	1280	.
O	1280	1281	4
O	1282	1287	years
O	1288	1289	(
O	1289	1294	range
O	1294	1295	,
O	1296	1297	4
O	1297	1298	.
O	1298	1299	6
O	1299	1300	-
O	1300	1301	6
O	1301	1302	.
O	1302	1303	0
O	1304	1309	years
O	1309	1310	)
O	1310	1311	.

O	1312	1326	Questionnaires
O	1327	1331	were
O	1332	1344	administered
O	1345	1351	before
O	1352	1361	treatment
O	1361	1362	,
O	1363	1368	every
O	1369	1370	6
O	1371	1377	months
O	1378	1381	for
O	1382	1384	60
O	1385	1391	months
O	1392	1395	and
O	1396	1398	at
O	1399	1401	72
O	1402	1408	months
O	1408	1409	.

O	1410	1417	Primary
O	1418	1421	QOL
O	1422	1425	end
O	1426	1432	points
O	1433	1437	were
O	1438	1441	the
B-outcome-Measure	1442	1444	SF
I-outcome-Measure	1444	1445	-
I-outcome-Measure	1445	1447	36
I-outcome-Measure	1448	1456	physical
I-outcome-Measure	1457	1458	(
I-outcome-Measure	1458	1461	PCS
I-outcome-Measure	1461	1462	)
O	1463	1466	and
B-outcome-Measure	1467	1473	mental
I-outcome-Measure	1474	1475	(
I-outcome-Measure	1475	1478	MCS
I-outcome-Measure	1478	1479	)
I-outcome-Measure	1480	1489	component
I-outcome-Measure	1490	1499	summaries
O	1499	1500	.

O	1501	1506	Among
O	1507	1512	women
O	1513	1515	in
O	1516	1519	the
O	1520	1523	QOL
O	1524	1532	analysis
O	1532	1533	,
O	1534	1538	mean
O	1539	1542	PCS
O	1542	1543	,
O	1544	1547	MCS
O	1547	1548	,
O	1549	1552	and
O	1553	1556	CES
O	1556	1557	-
O	1557	1558	D
O	1559	1565	scores
O	1566	1574	worsened
O	1575	1583	modestly
O	1584	1588	over
O	1589	1592	the
O	1593	1598	study
O	1598	1599	'
O	1599	1600	s
O	1601	1603	60
O	1604	1610	months
O	1610	1611	,
O	1612	1616	with
O	1617	1619	no
O	1620	1631	significant
O	1632	1642	difference
O	1643	1650	between
O	1651	1654	the
O	1655	1664	tamoxifen
O	1665	1666	(
O	1666	1667	n
O	1668	1669	=
B-intervention-participants	1670	1673	973
O	1673	1674	)
O	1675	1678	and
O	1679	1689	raloxifene
O	1690	1691	(
O	1691	1692	n
O	1693	1694	=
B-control-participants	1695	1699	1010
O	1699	1700	)
O	1701	1707	groups
O	1708	1709	(
O	1709	1710	P
O	1710	1711	>
O	1711	1712	.
O	1712	1713	2
O	1713	1714	)
O	1714	1715	.

B-outcome	1716	1722	Sexual
I-outcome	1723	1731	function
O	1732	1735	was
O	1736	1744	slightly
O	1745	1751	better
O	1752	1755	for
O	1756	1768	participants
O	1769	1777	assigned
O	1778	1780	to
O	1781	1790	tamoxifen
O	1791	1792	(
O	1792	1795	age
O	1795	1796	-
O	1796	1804	adjusted
O	1805	1813	repeated
O	1814	1821	measure
O	1822	1826	odds
O	1827	1832	ratio
O	1832	1833	,
O	1834	1835	1
O	1835	1836	.
O	1836	1838	22
O	1838	1839	%
O	1839	1840	;
O	1841	1843	95
O	1843	1844	%
O	1845	1847	CI
O	1847	1848	,
O	1849	1850	1
O	1850	1851	.
O	1851	1853	01
O	1853	1854	-
O	1854	1855	1
O	1855	1856	.
O	1856	1858	46
O	1858	1859	)
O	1859	1860	.

O	1861	1863	Of
O	1864	1867	the
O	1868	1873	women
O	1874	1876	in
O	1877	1880	the
O	1881	1888	symptom
O	1889	1899	assessment
O	1900	1908	analyses
O	1908	1909	,
O	1910	1913	the
B-control-participants	1914	1918	9769
O	1919	1921	in
O	1922	1925	the
O	1926	1936	raloxifene
O	1937	1942	group
O	1943	1951	reported
O	1952	1959	greater
B-outcome	1960	1964	mean
I-outcome	1965	1972	symptom
I-outcome	1973	1981	severity
O	1982	1986	over
O	1987	1989	60
O	1990	1996	months
O	1997	1999	of
O	2000	2011	assessments
O	2012	2016	than
O	2017	2020	the
B-intervention-participants	2021	2025	9743
O	2026	2028	in
O	2029	2032	the
O	2033	2042	tamoxifen
O	2043	2048	group
O	2049	2052	for
B-outcome	2053	2068	musculoskeletal
I-outcome	2069	2077	problems
O	2078	2079	(
B-iv-cont-mean	2079	2080	1
I-iv-cont-mean	2080	2081	.
I-iv-cont-mean	2081	2083	15
O	2084	2086	vs
B-cv-cont-mean	2087	2088	1
I-cv-cont-mean	2088	2089	.
I-cv-cont-mean	2089	2091	10
O	2091	2092	,
O	2093	2094	P
O	2095	2096	=
O	2097	2098	.
O	2098	2101	002
O	2101	2102	)
O	2102	2103	,
B-outcome	2104	2115	dyspareunia
O	2116	2117	(
B-iv-cont-mean	2117	2118	0
I-iv-cont-mean	2118	2119	.
I-iv-cont-mean	2119	2121	78
O	2122	2124	vs
B-cv-cont-mean	2125	2126	0
I-cv-cont-mean	2126	2127	.
I-cv-cont-mean	2127	2129	68
O	2129	2130	,
O	2131	2132	P
O	2132	2133	<
O	2133	2134	.
O	2134	2137	001
O	2137	2138	)
O	2138	2139	,
O	2140	2143	and
B-outcome	2144	2150	weight
I-outcome	2151	2155	gain
O	2156	2157	(
B-iv-cont-mean	2157	2158	0
I-iv-cont-mean	2158	2159	.
I-iv-cont-mean	2159	2161	82
O	2162	2164	vs
B-cv-cont-mean	2165	2166	0
I-cv-cont-mean	2166	2167	.
I-cv-cont-mean	2167	2169	76
O	2169	2170	,
O	2171	2172	P
O	2172	2173	<
O	2173	2174	.
O	2174	2177	001
O	2177	2178	)
O	2178	2179	.

O	2180	2185	Women
O	2186	2188	in
O	2189	2192	the
O	2193	2202	tamoxifen
O	2203	2208	group
O	2209	2217	reported
O	2218	2225	greater
B-outcome	2226	2230	mean
I-outcome	2231	2238	symptom
I-outcome	2239	2247	severity
I-outcome	2248	2251	for
I-outcome	2252	2265	gynecological
I-outcome	2266	2274	problems
O	2275	2276	(
B-iv-cont-mean	2276	2277	0
I-iv-cont-mean	2277	2278	.
I-iv-cont-mean	2278	2280	29
O	2281	2283	vs
B-cv-cont-mean	2284	2285	0
I-cv-cont-mean	2285	2286	.
I-cv-cont-mean	2286	2288	19
O	2288	2289	,
O	2290	2291	P
O	2291	2292	<
O	2292	2293	.
O	2293	2296	001
O	2296	2297	)
O	2297	2298	,
B-outcome	2299	2308	vasomotor
I-outcome	2309	2317	symptoms
O	2318	2319	(
B-iv-cont-mean	2319	2320	0
I-iv-cont-mean	2320	2321	.
I-iv-cont-mean	2321	2323	96
O	2324	2326	vs
B-cv-cont-mean	2327	2328	0
I-cv-cont-mean	2328	2329	.
I-cv-cont-mean	2329	2331	85
O	2331	2332	,
O	2333	2334	P
O	2334	2335	<
O	2335	2336	.
O	2336	2339	001
O	2339	2340	)
O	2340	2341	,
B-outcome	2342	2345	leg
I-outcome	2346	2352	cramps
O	2353	2354	(
B-iv-cont-mean	2354	2355	1
I-iv-cont-mean	2355	2356	.
I-iv-cont-mean	2356	2358	10
O	2359	2361	vs
B-cv-cont-mean	2362	2363	0
I-cv-cont-mean	2363	2364	.
I-cv-cont-mean	2364	2366	91
O	2366	2367	,
O	2368	2369	P
O	2369	2370	<
O	2370	2371	.
O	2371	2374	001
O	2374	2375	)
O	2375	2376	,
O	2377	2380	and
B-outcome	2381	2388	bladder
I-outcome	2389	2396	control
I-outcome	2397	2405	symptoms
O	2406	2407	(
B-iv-cont-mean	2407	2408	0
I-iv-cont-mean	2408	2409	.
I-iv-cont-mean	2409	2411	88
O	2412	2414	vs
B-cv-cont-mean	2415	2416	0
I-cv-cont-mean	2416	2417	.
I-cv-cont-mean	2417	2419	73
O	2419	2420	,
O	2421	2422	P
O	2422	2423	<
O	2423	2424	.
O	2424	2427	001
O	2427	2428	)
O	2428	2429	.

O	2430	2432	No
O	2433	2444	significant
O	2445	2456	differences
O	2457	2464	existed
O	2465	2472	between
O	2473	2476	the
O	2477	2486	tamoxifen
O	2487	2490	and
O	2491	2501	raloxifene
O	2502	2508	groups
O	2509	2511	in
B-outcome	2512	2519	patient
I-outcome	2519	2520	-
I-outcome	2520	2528	reported
I-outcome	2529	2537	outcomes
I-outcome	2538	2541	for
I-outcome	2542	2550	physical
I-outcome	2551	2557	health
I-outcome	2557	2558	,
I-outcome	2559	2565	mental
I-outcome	2566	2572	health
I-outcome	2572	2573	,
I-outcome	2574	2577	and
I-outcome	2578	2588	depression
O	2588	2589	,
O	2590	2598	although
O	2599	2602	the
O	2603	2612	tamoxifen
O	2613	2618	group
O	2619	2627	reported
O	2628	2634	better
B-outcome	2635	2641	sexual
I-outcome	2642	2650	function
O	2650	2651	.

O	2652	2660	Although
O	2661	2665	mean
O	2666	2673	symptom
O	2674	2682	severity
O	2683	2686	was
O	2687	2690	low
O	2691	2696	among
O	2697	2702	these
O	2703	2717	postmenopausal
O	2718	2723	women
O	2723	2724	,
O	2725	2730	those
O	2731	2733	in
O	2734	2737	the
O	2738	2747	tamoxifen
O	2748	2753	group
O	2754	2762	reported
O	2763	2767	more
O	2768	2781	gynecological
O	2782	2790	problems
O	2790	2791	,
O	2792	2801	vasomotor
O	2802	2810	symptoms
O	2810	2811	,
O	2812	2815	leg
O	2816	2822	cramps
O	2822	2823	,
O	2824	2827	and
O	2828	2835	bladder
O	2836	2843	control
O	2844	2852	problems
O	2852	2853	,
O	2854	2861	whereas
O	2862	2867	women
O	2868	2870	in
O	2871	2874	the
O	2875	2885	raloxifene
O	2886	2891	group
O	2892	2900	reported
O	2901	2905	more
O	2906	2921	musculoskeletal
O	2922	2930	problems
O	2930	2931	,
O	2932	2943	dyspareunia
O	2943	2944	,
O	2945	2948	and
O	2949	2955	weight
O	2956	2960	gain
O	2960	2961	.
O	2962	2976	clinicaltrials
O	2976	2977	.
O	2977	2980	gov
O	2981	2991	Identifier
O	2991	2992	:
O	2993	3004	NCT00003906
O	3004	3005	.
